Cardiac Amyloidosis Market Size Projected To Reach 8.1 Billion By 2034 With A Cagr Of 9%

We've updated all our reports with current data on tariff changes, trade developments, and supply chain shifts affecting key industries.

What Is the Projected Growth of the Cardiac Amyloidosis Market?
In recent times, the market size of cardiac amyloidosis has seen significant growth. With the current projections, it is expected to increase from a market value of $5.26 billion in 2024 to $5.75 billion in 2025, with a compound annual growth rate (CAGR) of 9.2%. The causes of this growth during the historical period can be traced back to a rise in amyloidosis-related conditions, an increase in genetic mutations, heightened awareness, a surge in the number of transthyretin amyloidosis cases, and an elevated geriatric population.

The market size for cardiac amyloidosis is projected to experience robust expansion in the upcoming years. By 2029, this market is estimated to reach $8.10 billion with a compound annual growth rate (CAGR) of 9.0%. Factors contributing to this estimated growth during the forecast period include improved diagnosis rates, government backing and initiatives, escalating instances of genetic mutations and supportive programs for patients. Future trends within this timeline feature developments in fresh therapies such as vulrisiran, growing research in the field of gene therapy, a focus on precision medicine, leaps forward in diagnostic technologies, and the creation of innovative therapies.

Purchase the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21128

What Are the Different Cardiac Amyloidosis Market Segments?
The cardiac amyloidosis market covered in this report is segmented -

1) By Product Type: Light Chain Amyloidosis, Transthyretin Amyloidosis
2) By Treatment: Chemotherapy, Surgery, Supportive Care, Stem Cell Transplant, Targeted Therapy
3) By End-User: Hospitals, Ambulatory Surgical Centres, Clinics

Subsegments:
1) By Light Chain Amyloidosis: Immunoglobulin Light Chain (AL) Amyloidosis, Primary Light Chain Amyloidosis, Secondary Light Chain Amyloidosis
2) By Transthyretin Amyloidosis: Hereditary Transthyretin Amyloidosis (ATTRm), Wild-type Transthyretin Amyloidosis (ATTRwt)

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21128&type=smp

What Are the Primary Drivers Shaping the Cardiac Amyloidosis Market?
The growth of the cardiac amyloidosis market is predicted to be driven by the escalating number of elderly people. Typically considered to be those aged 65 and above, the elderly population may need specialized health services and support due to changes related to aging. Factors such as increasing lifespan, improvements in healthcare, and decreasing birth rates contribute to the growth of this elderly population. The rise in the elderly population leads to an increase in cardiac amyloidosis cases, given that aging is a significant risk factor for the accumulation of amyloid protein in the heart. For example, data from the US-based nonprofit organization, Population Reference Bureau, in January 2024, project an increase in the US population aged 65 and older from 58 million in 2022 to 82 million by 2050, reflecting a 47% increase. Consequently, the expanding elderly population is expected to drive the cardiac amyloidosis market.

Which Companies Are Leading in the Cardiac Amyloidosis Market?
Major companies operating in the cardiac amyloidosis market are Pfizer Inc., Sanofi S.A., AstraZeneca plc, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Novo Nordisk A/S, Alexion Pharmaceuticals Inc., Dr. Reddy's Laboratories, Alnylam Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., Akcea Therapeutics Inc., BridgeBio Pharma Inc., Prothena Corp, Intellia Therapeutics Inc., Amylyx Pharmaceuticals, Neurimmune AG, SOM Biotech, Oncopeptides, Attralus Inc., Eidos Therapeutics.

What Cardiac Amyloidosis Market Trends Are Gaining Traction Across Different Segments?
Primary firms in the cardiac amyloidosis market are emphasizing on technological advancements, including artificial intelligence (AI)-aided software-only diagnostic technologies, to promote early detection and augment clinical results for patients suffering from this often undiagnosed condition. A medical device, powered by AI and requiring no additional hardware or intense clinical data, is capable of analyzing echocardiographic pictures and recognizing signs of the disease. For example, in November 2024, UK-based Ultromics Ltd. gained FDA approval for its AI-driven clinical tool, EchoGo Amyloidosis, designed for the early detection of cardiac amyloidosis. Remarkably, it is the first device in the FDA's Total Product Lifecycle Advisory Program (TAP) to be granted marketing consent. EchoGo Amyloidosis leverages AI to scrutinize echocardiograms and identify the disease from a single clip, catering to the pressing need for earlier detection before its unnoticed progression.

Get the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/report/cardiac-amyloidosis-global-market-report

What Are the Top Revenue-Generating Geographies in the Cardiac Amyloidosis Market?
North America was the largest region in the cardiac amyloidosis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cardiac amyloidosis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Frequently Asked Questions:
1. What Is the Market Size and Growth Rate of the Cardiac Amyloidosis Market?
2. What is the CAGR expected in the Cardiac Amyloidosis Market?
3. What Are the Key Innovations Transforming the Cardiac Amyloidosis Industry?
4. Which Region Is Leading the Cardiac Amyloidosis Market?

Why This Report Matters:

Competitive overview: This report analyzes the competitive landscape of the 3D imaging software market, evaluating key players on market share, revenue, and growth factors.

Informed Decisions: Understand key strategies related to products, segmentation, and industry trends.

Efficient Research: Quickly identify market growth, leading players, and major segments.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.